Analyst Reco. CureVac N.V.

Equities

Delayed Nasdaq Other stock markets 03:47:06 2024-05-28 pm EDT			5-day change	1st Jan Change
3.62 ^USD	-1.90%		+10.03%	-14.01%

03:40pm	CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	MT
May. 23	CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

CUREVAC : Significant cash drain in the Q1	May. 23
CUREVAC : A missed opportunity	May. 02
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	Apr. 26	MT
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	Apr. 25	MT
Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10	Dec. 22	MT
CUREVAC : An untrimmed pipeline becomes costly	Nov. 29
CUREVAC : Unchanged cash drain	Nov. 28
CUREVAC : A missed opportunity	23-08-21
CUREVAC : Higher losses expected in future	23-07-25
CUREVAC : Some glimpse of positive pipeline developments	23-06-21
SVB Securities Initiates CureVac at Outperform With $13 Price Target	23-06-08	MT
CUREVAC : Runway prolonged	23-05-30
CUREVAC : One big point despite many misses	23-05-02
JMP Securities Adjusts Price Target on CureVac to $24 From $34, Maintains Outperform Rating	23-04-26	MT
CUREVAC : Everything hangs on the decision of the new CEO	23-03-16
UBS Upgrades CureVac to Buy From Neutral, Adjusts Price Target to $18 From $8	23-01-19	MT
CUREVAC : UBS raises its recommendation to Buy	23-01-19	ZD
Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup	23-01-09	DJ
Jefferies Upgrades CureVac to Buy From Hold	23-01-09	MT
CUREVAC : Berenberg reaffirms its Buy rating	23-01-06	ZD

No results for this search

CUREVAC : Significant cash drain in the Q1

May 23, 2024 at 03:49 pm EDT